Guideline: Vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis)

Mycoses

Volumn 58, Issue S1, 2015, Pages 1-15

  Mendling, Werner ^a  

^a Deutsches Zentrum fuer Infektionen in Gynaekologie und Geburtshilfe   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CICLOPIROXOLAMINE; CLOTRIMAZOLE; ECONAZOLE; ESTROGEN; FENTICONAZOLE NITRATE; FLUCONAZOLE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; MANNOPROTEIN; MICAFUNGIN; MICONAZOLE NITRATE; NYSTATIN; ORAL CONTRACEPTIVE AGENT; POLYENE; POSACONAZOLE; PYRROLE DERIVATIVE; SIDEROPHORE; SKIN CREAM; TRIAZOLE DERIVATIVE; VIRULENCE FACTOR; ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; DYSPAREUNIA; DYSURIA; ESTROGEN BLOOD LEVEL; FUNGAL COLONIZATION; FUNGAL VIRULENCE; GENETIC POLYMORPHISM; GYNECOLOGICAL EXAMINATION; HUMAN; IMMUNOTHERAPY; INTRAVAGINAL DRUG ADMINISTRATION; LACTOBACILLUS; MEYEROZYMA GUILLIERMONDII; MICROSCOPY; NONHUMAN; PH MEASUREMENT; PHASE CONTRAST MICROSCOPY; PICHIA KUDRIAVZEVII; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT INFECTION; RISK FACTOR; SELF CARE; SEROLOGY; SYSTEMATIC REVIEW; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA PAIN; VAGINAL BURNING SENSATION; VAGINAL PRURITUS; CANDIDIASIS, VULVOVAGINAL; DRUG EFFECTS; FEMALE; GERMANY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; ISSATCHENKIA ORIENTALIS; LACTOBACILLUS; SACCHAROMYCES CEREVISIAE;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS, VULVOVAGINAL; FEMALE; GERMANY; HUMANS; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, PHASE-CONTRAST; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VAGINAL DISCHARGE;

EID: 84923262938     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12292     Document Type: Article

References (161)

1. Aballéa S, Guelfucci F, Wagner J et al. Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes 2013; 11: 169-73.
2. Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA 2004; 291: 1368-79.
3. Auger P, Joly J. Microbial flora associated with Candida albicans vulvovaginitis. Am J Obstet Gynecol 1980; 55: 397-401.
4. Auler ME, Morreiva D, Rodriguez FF et al. Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis. Med Mycol 2010; 48: 211-6.
5. Babula O, Lazdane G, Kroica J, Linhares JM, Ledger WJ, Witkin SS. Frequency of interlenkin-4 (IL-4)-589 gene polymorphism and vaginal concentrations of IL - 4, nitric oxide, and mannose binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40: 1258-62.
6. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 2004; 104: 926-30.
7. de Bernardis F, Agatensi L, Ross IK et al. Evidence for a role for secretory aspartate proteinase of Candida albicans in vulvovaginal candidosis. J Infect Dis 1990; 161: 1276-83.
8. de Bernardis F, Boccanera M, Cassone A. The role of immunity against vaginal Candida infection. In: Fidel PL, Huffnagle GB, (eds), Fungal Immunity: from an Organ Perspective. Heidelberg, New York: Springer, 2005; 345-55.
9. Bisshop MPJM, Merkus JMWM, Schleygrond H, van Cutsem J. Co-treatment of the male partner in vaginal candidosis: a double-blind randomised controlled-study. Br J Obstet Gynecol 1986; 93: 79-81.
10. Blaschke-Hellmessen R. Subpartale Übertragung von Candida und ihre Konsequenzen. Vertical transmission of Candida and its consequences. Mycoses 1998; 41(Suppl. 2): 31-6.
11. Blaschke-Hellmessen R. Epidemiologische Untersuchungen zum Vorkommen von Hefepilzen bei Kindern und deren Müttern. Mykosen 1968; 11: 611-6.
12. Bohanna NJ. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care 1998; 21: 451-6.
13. Bond CM, Watson MC, Grampian Evidence Based Community Pharmacy Guidelines Group. The development of evidence-based guidelines for over-the-counter treatment of vulvovaginal candidiasis. Pharm World Sci 2003; 25: 177-81.
14. Buch A, Skytte-Christensen E. Treatment of vaginal candidosis with natamycin and effect of treating the partner at the same time. Acta Obstet Gynecol Scand 1982; 61: 393-6.
15. della Casa V, Noll H, Gonser S, Grob P, Graf F, Pohlig G. Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforsch 2002; 52: 699-705.
16. Cassone A, de Bernardis F, Mondell F, Ceddia T, Agatensil L. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Inf Dis 1987; 156: 777-82.
17. Cassone A, de Bernardis F, Torososantucci A. An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis. Curr Mol Med 2005; 5: 377-82.
18. Cassone A, Casadevall A. Recent progress in vaccines against fungal diseases. Curr Opin Microbiol 2012; 4: 427-33, doi:10.1016/j.mib.2012.04.004.
19. Cetin M, Ocak S, Gungoren A, Hakverdi AU. Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods. Scand J Infect Dis 2007; 39: 584-8.
20. Chaim W, Foxman B, Sobel JD. Association of recurrent vaginal Candidiasis and secretory ABO and Lewis phenotype. J Inf Dis 1997; 176: 828-30.
21. Chassot F, Negri MF, Swidsinski AF et al. Can intrauterine contraceptive devices be a Candida albicans reservoir? Contraception 2008; 77: 355-9.
22. Cohen L. Is more than one application of an antifungal necessary in the treatment of an acute vaginal candidosis? Am J Obstet Gynecol 1985; 152: 961-4.
23. Corsello S, Spinillo A, Osnengo G et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 2003; 110: 66-72.
24. Czeisel MT, Rockenbauer M. No teratogenic effect after clotrimazole therapy during pregnancy. Epidemiology 1999; 10: 437-40.
25. Czeizel AE, Fladung B, Varga P. Preterm birth reduction after clotrimazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 116: 157-63.
26. Czeisel AE, Puho EH, Kazu Z. The use of data set of the Hungarian case - control surveillance of congenital abnormalities for evaluation of birth outcomes begoud birth defects. Centr Eur J Public Health 2007; 15: 147-53.
27. Davidson F, Mould RF. Recurrent vaginal candidosis in women and the effect of intermittent prophylactic treatment. BJ Vener Dis 1978; 54: 176-83.
28. Davidson F, Oates JK. The pill does not cause thrush- Brit J Obstet Gynecol 1985; 92: 1265.
29. Dennerstein GJ, Ellis DH. Oestrogen, glycogen and vaginal candidiasis. Austr. NZ J Obstet Gynecol 2001; 41: 326-8.
30. Donders G, Babula O, Bellen G, Linhares IM, Witkin SS. Mannose-bindling lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008; 115: 1223-31.
31. Donders G, Bellen G, Byttebier G et al. Individualized decreasing dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol 2008; 199: 613 e1-9.
32. Donders G, Prenen H, Verbeke G, Reybrouck R. Impaired tolerance for glucose in women with recurrent vaginal candidiasis. Am J Obstet Gynecol 2002; 187: 989-93.
33. Donders GG, Bellen G, Mendling W. Management of recurrent vulvovaginal candidosis as a chronic illness. Gynecol Obstet Invest 2010; 70: 306-21.
34. Eckert Hawes SE et al. Vulvovaginal candidiasis: clinical manifestations, risk factors management algorithm. Gynecol 1998; 92: 757-65.
35. Ehrström SM, Kornfeld D, Thuresson J, Rylander E. Signs of chronic stress in women with recurrent candida vulvovaginitis. Am J Obstet Gynecol 2005; 193: 1376-81.
36. Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. A Antimicrob Chemother. 2006; 58: 266-72.
37. Farmer MA, Taylor AM, Bailey AL et al. Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia. Sci Transl Med 2011; 3: 101ra91.
38. Farrell SM, Hawkins DF, Ryder TT. Scanning electron microscope study of Candida albicans, invasion of cultural human cervical epithelial cells. Sabouraudia 1983; 25: 251-4.
39. Ferris GD, Nyirjesy P, Sobel JD, Soper D, Pavlitic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient diagnosed Fong 1992 vulvovaginal candidosis. Obstet Gynecol 2002; 99: 419-25.
40. Ferwerda B, Ferwerda B, Platinga TS et al. Human lectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361: 1760-7.
41. Fidel Jr. PL. Immunity in vaginal candidiasis. Curr Opin Infect Dis 2005; 18: 107-11.
42. Fidel Jr. PL, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80-96.
43. Fong JW. The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourin Med 1992; 68: 374-7.
44. Foxman B. The epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Health 1990; 80: 329-31.
45. Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. Low Genit Tract Dis 2012; 17: 1-6.
46. Friese K, Neumann G, Siebert J. Topical antiseptics as an alternative in the treatment of acute vulvovaginal candidosis. Arch Gynecol Obstet 2003; 268: 194-7.
47. Frey Tirri B. Antimicrobial topical agents used in the vagina. Curr Probl Dermatol 2011; 40: 36-47.
48. Gaspard U, Scheen A et al. Randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinyl estradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception 2003; 67: 423-9.
49. Geraldo P, Neuer A, Korneeva IL, Ribeiro-Filho A, Simoes JA, Witkin SS. Vaginal heat shock protein expression in symptom-free women with history of recurrent vulvovaginitis. Am J Obstet Gynecol 1999; 180: 524-9.
50. Ghannoum MA, Abu-El Teen KH. Pathogenicity determinants of Candida. Mycoses 1990; 33: 265-82.
51. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 2000; 13: 122-43.
52. Goswami R, Dadhwal V, Tejaswi S et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect Dis 2000; 41: 162-6.
53. Goswami D, Goswami R, Banerjee U et al. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect 2006; 52: 111-7.
54. Hay PH, Czeizel AE. Asymptomatic trichomonas and candida colonization and pregnancy outcome. Best Pract Res Clin Obstet Gynecol 2007; 21: 403-9.
55. Hettiarachchi N, Ashbee HR, Wilson JD. Prevalence and management of non-albicans vaginal candidiasis. Sex transm Infect 2010; 86: 99-100.
56. Hilton E, Isenberg HD, Alperstein P et al. Ingestion of yoghourt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992; 116: 353-7.
57. Hoffstetter SE, Barr S, LeFevre C, Leong FC, Leet T. Self-reported yeast symptoms compared with clinical wet mount analysis and vaginal yeast culture in a specialty clinic setting. J Reprod Med 2008; 53: 402-6.
58. Holland S, Vinh D. Yeast infections - human genetics in the rise. N Engl J Med 2009; 361: 1798-801.
59. Ip WK, Lan YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in Phagocytosis by human dendritic cells. J Inf Dis 2004; 190: 632-40.
60. Ismail A, Lupan DM. Utilisation of siderophores by Candida albicans. Mycopath 1986; 96: 109-13.
61. Jeavons HS. Prevention and treatment of vulvovaginal candidosis using exogenous lactobacilli. J Obstet Gynecol Neonatal Nurs 2003; 32: 287-96.
62. De Jong MA, Vriend LE, Theelen B et al. C-type lectin Langerhans is a beta-glucan receptor on human Langerhans cells that recognize opportunistic and pathogenic fungi. Mol Immunol 2010; 47: 1216-25.
63. Kiss H, Petricevicz L, Husslein P. Prospective randomised controlled trial of an infection screening program to reduce the rate of preterm delivery. BMJ 2004; 329: 371-5.
64. Koldowsky H, Kariger U, Mendling W. Herstellung eines autologen membrangebundenen Candida-Antigens und in-vitro-Untersuchungen zu seinen immunologischen Reaktionen. In Metzner G, Weissenbacher ER (Hrsg.) (eds), Candida-Infektionen des weiblichen Genitaltraktes. München: Medifact 1999; 25-32.
65. Kunzelmann V, Tietz HJ, Roßner D et al. Voraussetzungen für eine effektive Therapie chronisch rezidivierender Vaginalkandidosen. Mycoses 1996; 39(Suppl. 1): 65-72.
66. Lattif AA, Prasard R et al. The glyzolate cycle enzyme activities in the pathogenetic isolates of Candida albicans obtained from HIV/AIDS, diabetic and burn patients. Mycoses 2006; 49: 85-89.
67. de Leon E, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type I and type 2 diabetes. BMC Infect Dis 2002; 2: 1-6.
68. Li J, Fan SR, Liu XP et al. Biased genotype distributions of Candida albicans strains associated with vulvovaginal candidosis and candidal balanoposthitis in China. Clin Infect Dis 2008; 47: 1119-25.
69. Loeffler W. Terminologie der Humanmykosen. Mykosen 1983; 26: 346.
70. Lowe NK, Neal JL, Ryan-Wenger NA. Accuracy of the clinical diagnosis of vaginitis compared with a DNA probe laboratory standard. Obstet Gynecol 2009; 113: 89-95.
71. Mailänder-Sanchez D, Wagener I. Potential role of probiotic bacteria in the treatment and prevention of localised candidosis. Mycoses 2012; 55: 17-26.
72. Martinez RC, Seney SL, Summers KL, Nomitzo A, de Martinis FC, Reid G. Effect of Lactobacillus rhamsosus GR-1 and Lactobacillus reuteri RC-14 on the ability of Candida albicans to infect cells and include inflammation. Microbiol Immunol 2009; 53: 487-95.
73. Mastroiacovo P, Mazzone T, Botto LD. Prospective assessment of pregnancy outcome after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996; 176: 1645-50.
74. Mathema B, Cross E, Dun E et al. Prevalence of vaginal colonization by drug-resistent candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Inf Dis 2001; 33: E23-7.
75. Meinhof W. Die Salzsäure-Toleranz von Candida albicans. Mykosen 1974; 17: 339-47.
76. Mendling W. Die Torulopsidose in der Frauenheilkunde. Geburtsh Frauenheilk 1984; 44: 583-6.
77. Mendling W. Azoles in the therapy of vaginal candidosis. In: Berg D, Plempel M (eds), Sterol Biosynthesis Inhibitors. Chichester: Ellis Horwood, 1988; 480-506.
78. Mendling W, Koldovsky U. Investigations by cell-mediated immunologic tests of therapeutic trials with thymopentin in vaginal mycoses. Inf Dis Obstet Gynecol 1996a; 4: 225-31.
79. Mendling W, Gutschmidt J, Gantenberg R, Andrade P, Schönian G. Vergleich der Stammspezifität von Hefepilzen verschiedener Lokalisationen bei Frauen mit Vaginalcandidosen und deren Partnern. Mycoses 1998; 41(Suppl. 2): 22-25.
80. Mendling W, Krauss C, Fladung B. A clinical multi-center-study comparing afficacy and tolerability of topical combination therapy with Clotrimazole (Canesten, two formats) with oral single dose fluconazole (Diflucan) in vulvovaginal mycoses. Mycoses 2004; 47: 136-42.
81. Mendling W, Niemann D, Tintelnot K. Vaginal Colonisation with Candida Species with Special Focus on Candida dubliniensis. A Prospective Study. Geburtsh Frauenheilk 2007; 67: 1132-7.
82. Mendling W, Seebacher C. Vulvovaginalkandidose. AWMF-Guideline 013/004 (S1) 2008.
83. Mendling W. Vaginose, Vaginitis, Zervizitis und Salpingitis, 2nd edn. Heidelberg: Springer, 2006.
84. Mendling W, Spitzbart H. Antimykotische Therapie der vaginalen Hefepilz-Kolonisation von Schwangeren zur Verhütung von Kandidamykosen beim Neugeborenen. AMWF, Guideline 015/042 (S 1) 2008
85. Mendling W, Birkner V. Die Vakzination mit inaktivierten Laktobazillen oder Heliotherapie kann die Lebensqualität von Frauen mit chronisch rezidivierender vulvovaginaler Kandidose verbessern. - Eine prospektive, 3-armige randomisierte Studie. Geburtsh Frauenheilk 2011; 71: 767-72.
86. Mendling W, Schlegelmilch R. Die 3tägige Kombinationsbehandlung der Vulvovaginalkandidose mit Clotrimazol 200 mg Vaginaltabletten und Clotrimazol Crème für die Vulva ist significant besser als die mit Vaginaltabletten allein. Eine ältere multizentrische, Plazebo-kontrollierte Doppelblindstudie und ihre Bedeutung für Therapieempfehlungen. Geburtsh Frauenheilk 2014; 74: 355-60.
87. Meyer H, Göttlicher S, Mendling W. Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antimycotic therapy. Mycoses 2006; 48: 202-9.
88. Molgaard-Nielsen D, Pasternak B, Hviid A. Use of fluconazole during pregnancy and risk of birth defects. N Engl J Med 2013; 369: 830-9.
89. Moraes PSA, de Lima Goiaba S, Taketoni EA,. Candida albicans allergen immunotherapy in recurrent vaginal candidiasis. Invest Allergol Clin Immunol 2000; 10: 305-9.
90. Müller J, Nold B, Kubitza D, Baumert J. Quantitative Untersuchungen über die Döderlein-Flora gesunder sowie mykosekranker Probandinnen unter lokaler Isoconazol-Nitrat-Therapie. In: Seeliger HPR (ed) Gyno - Travogen, Monographie Excerpta Medica. Amsterdam: Oxford Princeton 1981: 81-93.
91. Mylonas I, Bergauer F. Diagnosis of vaginal discharge by wet mount microscopy: a simple and underrated method. Obstet Gynecol Surv 2011; 66: 359-68.
92. Naglik J, Albrecht A, Bader O, Huber B. Candida albicans proteinases and host/pathogen interactions. Cell Microbiol 2004; 6: 915-26.
93. Neves NA, Carvallho LP, de Oliveira MA et al. Association between atopy and recurrent vaginal candidosis. Clin Exp Immunol 2005; 142: 167-71.
94. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B. Ciclopirox olamine treatment affects the expression pattern of metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 2003; 47: 1805-17.
95. Nurbhai M, Grimshaw J, Watson M, Bond C, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2007 Oct 17;(4): CD002845.
96. Nyirjesy P, Seeney SM, Grody MHT, Jordan CA, Buckeley HR. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol 1995; 173: 820-3.
97. Nyirjesy P, Alexander AB, Weitz MV. Vaginal candida parapsilosis: pathogen or bystander? Infect Dis Obstet Gynecol 2005; 13: 37-41.
98. Odds FC. Candida and Candidosis, 2nd edn. UK: Baillière Tindall, WB Saunders, 1988.
99. Odds FC, Arai T, Disalvo AF et al. Nomenclature of fungal diseases: a report and recommendations from a sub-Committee of the International Society for Human and Animal Mycology (ISHAM). J Med Vet Mycol 1992; 30: 1-10.
100. Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W. A 5-Year (2000-2004) epidemiological survey of Candida and non-candida yeasts species causing vulvovaginal candidiasis in Graz. Austria. Mycoses 2006; 49: 471-5.
101. Phillips AJ. Treatment of non-albicans candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol 2005; 192: 2009-12.
102. Pirotta MV, Gunn JM, Chondros P. 'Not thrush again' Women's experience of post-antibiotic vulvovaginitis. Med J Aust 2003; 179: 43-46.
103. Pirotta M et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomized controlled trial. BMJ 2004; 329: 548-51.
104. Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Mecrobiol 2006; 44: 3213-7.
105. Pitsoni E, Lavazzo C, Falagas ME. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomised controlled trials. Am J Obstet Gynecol 2008; 198: 153-60.
106. Plempel M. Pharmakokinetik der Imidazol-Antimykotika. Mykosen 1980; 23: 16-27.
107. Powell BL. Identification of a 173 - estradiol - binding protein in Candida albicans and Candida (Torulopsis) glabrata. Exp Mycology 1984; 8: 304.
108. Quereux C, Gelas B, Chevallier T, Petit F, Micheletti MC. Evaluation of the efficacy and speed of action of sertoconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis. Gynecol Obstet Fertil 2000; 28: 238-44.
109. Ray D, Goswami R, Bomerjee U et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007; 30: 312-7.
110. Raska M, Belakova J, Horynova M et al. Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90 - specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. Med Mycol 2008; 46: 420.
111. Reed BD, Zazone P, Pierson LL, Gorenflo DW, Horreocks J. Candida transmission and sexual behaviour as risk for a repeated episode of Candida vulvovaginitis. J Womens Health (Larchmt) 2003; 12: 979-89.
112. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 42: 2155-62.
113. Rigg D, Miller MM, Metzger WJ. Recurrent allergic vulvo-vaginitis treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990; 162: 332-6.
114. Ritter W. Pharmacokinetics of azole compounds. In: Berg D, Plempel M, (eds), Sterol Biosynthesis Inhibitors. Chichester: Ellis Horwood, 1988: 397-429.
115. Roberts CL, Rickard K, Kotsiou G, Morries JM. Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent preterm birth: an open-label pilot randomized controlled trial. BMC Pregnancy Childbirth 2011; 11: 18, doi: 10.1186/1471-2393-11-18
116. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011; 11: 275-88.
117. Romeo O, Criseo G. Candida Africana and its closest relatives. Mycoses 2011; 54: 475-86.
118. Rosedale N, Browne K. Hyposensitization in the management of recurring vaginal candidiasis. Ann Allergy 1979; 43: 250-3.
119. Roth AC, Milsom I, Forssman L, Wáhlén P. Intermittend prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourin Med 1990; 66: 357-60.
120. Rüchel R, Fegeler R, Trost M. Comparison of secretory proteinases from different strains of Candida albicans. Sabouraudia 1982; 20: 233-44.
121. Rusch K, Schwiertz A. Candida autovaccination in the treatment of vulvovaginal Candida infections. Int J Gynecol Obstet 2007; 96: 130.
122. Rylander E, Berglund A-L, Krassny C et al. Vulvovaginal candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sex Transm Infect 2004; 80: 54-57.
123. Savini V, Catavitello C, Manua A et al. Two cases of vaginitis caused by Itraconazole - resistant Saccharomyces cerevisiae and review of recently published studies. Mycopathologia 2008; 166: 47-50.
124. Scheklakow ND, Deletorski WW, Goldoa OA. Veränderungen der Ultrastruktur von Candida albicans unter Einwirkung von Polyen-Antibiotika. Mykosen 1980; 24: 140-52.
125. Schnell JD. Epidemiology and prevention of peripartal mycoses. Chemother 1982; 28 (Suppl. I): 66-72.
126. Schnell JD, Voigt WH. Das Verhalten von Sprosspilzen am nicht verhornenden Plattenepithel. Arch Gynaekol 1974; 217: 377-82.
127. Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis 2009; 64: 354-6.
128. Sharma C, Muralidhar S, Xu J, Meis JF, Chowdhary A. Multilocus sequence typing of Candida africana from patients with vulvovaginal candidiasis in New Delhi, India. Mycoses 2014; 57: 544-52.
129. Singh S, Sobel JD, Bhargava P, Boikov D, Vasquez JA. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Inf Dis 2002; 35: 1066-70.
130. Sobel JD. Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstet Gynecol 1985; 65: 435-40.
131. Sobel JD. Vaginitis due to Saccharomyces cereviseae: epidemiology, clinical aspects, and therapy. Clin Inf Dis 1993; 16: 93-99.
132. Sobel JD. Vulvovaginitis due to Candida glabrata. An emerging problem. Mycoses 1998; 41(Suppl. 2): 18-21.
133. Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369: 1961-71.
134. Sobel JD, Harold C, Wiesenfeld MD et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004; 351: 876-83.
135. Sobel JD, Myers PG, Kaye D, Leviston ME. Adherence of Candida albicans to human vaginal and buccal epithelial cells. J Infect Dis 1981; 143: 76-82.
136. Sobel JD, Zervos M, Reed BD et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003; 47: 34-38.
137. Spacek J, Jilek P, Buchtav V, Förstl M, Hronek M, Holeckova M. The serum levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidosis during attack, remission and in healthy controls. Mycoses 2005; 48: 391-5.
138. Spinillo A, Capuzzo E, Egbe TO, Baltaro P, Nicola S, Piazzi G. Torulopsis glabrata vaginitis. Obstet Gynecol 1995; 85: 993-8.
139. Swidsinski A, Loening-Baucke V, Swidsinski S et al. Infection through structured polymicrobial gardnerella biofilms (StPM-GB). Histol Histopathol 2014; 29: 567-87.
140. Tarry W, Fisher M, Shen S, Mawhinney M. Candida albicans: the estrogen target for vaginal colonization. J Surg Res 2005; 129: 278-82.
141. Thoden J, Potthoff A, Bogner JR et al. Therapy and prophylaxis of the opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066). Infection 2013; 41(Suppl 2): S91-115.
142. Thrumbore DJ, Sobel JD. Recurrent vulvovaginal candidiasis: vaginal epithelial cells susceptibility to Candida albicans adherence. Obstet Gynecol 1986; 67: 810-2.
143. Tietz HJ. Gezieltes Vorgehen gegen Problemkeime. Gyn Geburtsh 2009; 7-8: 41-44.
144. Tietz HJ. Candida glabrata: pathogenität und Stand der Dinge. Hautarzt 2012; 63: 868-71.
145. Upmalis DH, Cone FL, Lamia CA et al. Single-dose miconazole nitrate vaginal ovule in the treatment of vulvovaginal candidiasis: two single-blind, controlled studies versus miconazole nitrate 100 mg cream for 7 days. J Womens Health Gend Based Med 2000; 9: 421-9.
146. Vecciarelli A, Pericolini E, Pietrella D. New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges. Front Microbiol 2012; 3: 294, doi: 10.3389/fmicrobiol.2012.00294.
147. Vermitsky JP, Self MJ, Chadwick SG et al., Survey of vaginal flora-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008; 46: 1501-3.
148. Wajnberg M, Wajnberg A. Doppelblind-Vergleichsstudie mit Ciclopyroxolamin- und Miconazol-Vaginalcreme bei vulvovaginaler Kandidose. Mykosen 1981; 24: 721-30.
149. Walker PP, Reynolds MT, Ashbee HR, Bown C, Evans FG. Vaginal yeasts in the era of 'over the counter' antifungals. Sex Transm Infect 2000; 76: 437-238.
150. Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oval versus intravaginal imidazole and triazole antifungal treatment of uncomplicated Candidiasis (thrush): a systemic review. BJOG 2002; 109: 85-89.
151. Weissenbacher TM, Witkin SS, Gingelmaier A, Scholz C, Friese K, Mylonas I. Relationship between recurrent vulvovaginal candidosis and immune mediators in vaginal fluid. Eur J Obstet Gynecol Reprod Biol 2009; 144: 59-63.
152. Weissenbacher T, Witkin SS, Ledger WJ et al. Relationship between clinical diagnosis of recurrent vulvovaginal candidiasis and detection of candida species by culture and polymerase chain reaction. Arch Gynecol Obstet 2009; 279: 125-9.
153. van de Wijgert J, Verweijs MC, Turner AN, Morrison CS. Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission. AIDS 2013; 27: 2141-53.
154. Wilson C. Recurrent vulvovaginal candidiasis; an overview of traditional and alternative therapies. Adv Nurse Pract. 2005; 13: 24-29.
155. Witkin SS, Jeremias J, Ledger WJ. A localized vaginal allergic response in women with recurrent vaginitis. J Allergy Clin Immunol 1988; 81: 412-6.
156. Witkin SS, Giraldo P, Linhares D. New insights into the immune pathogenesis of recurrent vulvovaginal candidiasis. Int J Gynecol Obestet 2000; 3: 114-8.
157. Witt A, Kaufmann U, Bitschnau M et al. Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. BJOG 2009; 11: 1499-505.
158. Wozniak KL, Palmer G, Kutner R, Fidel Jr PL. Immunotherapeutic approaches to enhance protective immunity against Candida vaginitis. Med Mycol 2005; 43: 589-601.
159. Xu J, Schwartz K, Bartoces M, Monsur J, Severson RK, Sobel JD. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J Am Board Fam Med 2008; 21: 261-208.
160. Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush in pregnancy) (review). The Cochrane Database of systematic Reviews 2001; 4:CD 000225.
161. Von Zglinicki W. Die Hormonspirale als Ursache für chronische Infektionen. Dissertation (Prof. HJ Tietz), Charité 2011.